Sensitive and Easy-Read CRISPR Strip for COVID-19 Rapid Point-of-Care Testing

Rapid and clinically sensitive detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) play an important role in the contact tracing and containment of the COVID-19 pandemic. A recently developed field-deployable clustered regularly interspaced short palindromic repeats (CRISPR) detection assay with lateral flow strips shows promise for point-of-care detection of SARS-CoV-2. However, the limit of detection of paper strip-based assays (10-100 copies/mu L) is much lower than that of fluorescence-based detection methods. In this study, we developed an easy-readout and sensitive enhanced (ERASE) strip to visualize the results of CRISPR detection and improve the sensitivity to 1 copy/mu L with an unambiguous easy-read result. Using 649 clinical samples from blind specimens collected from patients in China, we validated our ERASE assay for SARS-CoV-2 RNA detection with 90.67% positive predictive agreement and 99.21% negative predictive agreement. In conclusion, our study provided a customized CRISPR strip for use in a simple, rapid, ultrasensitive, and highly specific assay for SARS-CoV-2 detection.

Automated summary

A study developed an enhanced strip for CRISPR detection of SARS-CoV-2, which improved sensitivity to 1 copy/μL and provided clear and easy-to-read results. Validation with clinical samples showed high positive predictive agreement (90.67%) and negative predictive agreement (99.21%) for SARS-CoV-2 RNA detection using this strip.